Phathom Pharmaceuticals

(NASDAQ) PHAT

Current Price$10.72

Market Cap$824.68M

Since IPO (2019)-56%

5 Year-69%

1 Year+12%

1 Month-0%

Phathom Pharmaceuticals Financials at a Glance

Market Cap

$824.68M

Revenue (TTM)

$204.89M

Net Income (TTM)

-$157.30M

EPS (TTM)

-$2.11

P/E Ratio

-4.90

Dividend

$0.00

Beta (Volatility)

1.36 (Average)

Dividend

$0.00

Beta (Volatility)

1.36 (Average)

Price

$10.72

Volume

68,382

Open

$10.48

Price

$10.72

Volume

68,382

Open

$10.48

Previous Close

$10.72

Daily Range

$10.10 - $10.76

52-Week Range

$7.61 - $18.31

Estimated Earnings Date

Aug 6, 2026

Dividend

$0.00

Beta (Volatility)

1.36 (Average)

Price

$10.72

Volume

68,382

Open

$10.48

Previous Close

$10.72

Daily Range

$10.10 - $10.76

52-Week Range

$7.61 - $18.31

Estimated Earnings Date

Aug 6, 2026

PHAT News

Phathom (PHAT) Q2 Revenue Jumps 441%

Motley Fool Markets TeamAug 7, 2025

Why Shares of Phathom Pharmaceutical Jumped This Week

James HalleyJan 28, 2023

PHAT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Phathom Pharmaceuticals

Industry

Pharmaceuticals

Sector

Health Care

Employees

371

CEO

Steven L. Basta, MBA

Website

www.phathompharma.com

Headquarters

Florham Park, NJ 07932, US

PHAT Financials

Key Financial Metrics (TTM)

Gross Margin

84.93%

Operating Margin

-47.15%

Net Income Margin

-76.77%

Return on Equity

39.24%

Return on Capital

N/A

Return on Assets

-51.55%

Earnings Yield

-20.41%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$824.68M

Shares Outstanding

79.76M

Volume

68.38K

Avg. Volume

1.18M

Financials (TTM)

Gross Profit

$174.02M

Operating Income

-$96.60M

EBITDA

-$90.89M

Operating Cash Flow

-$97.49M

Capital Expenditure

-$70.00K

Free Cash Flow

-$97.40M

Cash & ST Invst.

$180.90M

Total Debt

$166.30M

Phathom Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$58.30M

+104.4%

Gross Profit

$46.31M

+86.8%

Gross Margin

79.42%

N/A

Market Cap

$824.68M

N/A

Market Cap/Employee

$1.93M

N/A

Employees

427

N/A

Net Income

-$30.37M

+67.8%

EBITDA

-$14.46M

+81.0%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$180.90M

-14.8%

Total Debt

$166.30M

-70.5%

Accounts Receivable

$80.72M

+122.0%

Inventory

$6.51M

+105.6%

Long Term Debt

$165.64M

-69.7%

Short Term Debt

$667.00K

-96.2%

Return on Assets

-51.55%

N/A

Return on Invested Capital

-53.64%

N/A

Free Cash Flow

-$15.65M

+81.6%

Operating Cash Flow

-$15.65M

+81.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

SANASana Biotechnology, Inc.

SANASana Biotechnology, Inc.$3.42+4.91%

OCSOculis Holding AG

OCSOculis Holding AG$12.00+2.21%

BBOTBridgeBio Oncology Therapeutics Inc.

BBOTBridgeBio Oncology Therapeutics Inc.$7.40-3.77%

XNCRXencor, Inc.

XNCRXencor, Inc.$15.05+2.10%

BCAXBicara Therapeutics Inc. Common Stock

BCAXBicara Therapeutics Inc. Common Stock$26.87+2.01%

URGNUroGen Pharma Ltd.

URGNUroGen Pharma Ltd.$34.54+0.47%

SEPNSepterna Inc

SEPNSepterna Inc$37.34+8.11%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

AALAmerican Airlines Group

AALAmerican Airlines Group$17.87+0.02%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$153.23+0.00%

ONDSOndas

ONDSOndas$7.83+0.02%

KEELKeel Infrastructure

KEELKeel Infrastructure$6.03+0.03%

HLHecla Mining

HLHecla Mining$15.54+0.03%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.67+0.04%

TAT&T

TAT&T$22.72+0.01%

Questions About PHAT

What is the current price of Phathom Pharmaceuticals?

Phathom Pharmaceuticals is trading at $10.72 per share.

What is the 52-week range for Phathom Pharmaceuticals?

Over the past 52 weeks, Phathom Pharmaceuticals has traded between $7.61 and $18.31.

How much debt does Phathom Pharmaceuticals have?

As of the most recent reporting period, Phathom Pharmaceuticals reported total debt of $547.22M.

How much cash does Phathom Pharmaceuticals have on hand?

Phathom Pharmaceuticals reported $180.90M in cash and cash equivalents in its most recent financial results.

What is Phathom Pharmaceuticals’s dividend yield?

Phathom Pharmaceuticals does not currently have a dividend yield.

Phathom Pharmaceuticals

Phathom Pharmaceuticals Financials at a Glance

PHAT News

Phathom (PHAT) Q2 Revenue Jumps 441%

Why Shares of Phathom Pharmaceutical Jumped This Week

PHAT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Phathom Pharmaceuticals

PHAT Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Phathom Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About PHAT

What is the current price of Phathom Pharmaceuticals?

What is the 52-week range for Phathom Pharmaceuticals?

How much debt does Phathom Pharmaceuticals have?

How much cash does Phathom Pharmaceuticals have on hand?

What is Phathom Pharmaceuticals’s dividend yield?

Premium Investing Services